Jiangxi Biotech (06915): Over-allotment rights lapsed at the end of the price stabilization period

Zhitong Finance App News, Jiangxi Biotech (06915) announced that the price stability period for global sales will end on July 25, 2026 (that is, the 30th after the deadline for submitting the Hong Kong Public Sale Application). The overall coordinator did not exercise the over-allotment right during the price stabilization period, and the over-allotment right expired on July 25, 2026. Therefore, H shares are not and will not be issued based on over-allotment rights.

The price stabilization actions taken by China International Finance Hong Kong Securities Limited (as the price stabilizer operator) or any person acting on its behalf during the price stabilization period were as follows: over allocation of a total of 5.435 million H shares during the international sale; during the price stabilization period, a total of 5.435 million H shares were continuously purchased on the market at a price of HK$7.40 to HK$10.46 per H share for delivery to the undertaker. They have agreed to delay delivery of the relevant H shares subscribed under the global offering.